Summary The lipid core of human plasma low-density lipoprotein (LDL) was extracted using hexane and the LDL reconstituted with the addition of n-octyl-carborane. Biodistribution studies of the boronated LDL were performed in BALB/c mice bearing subcutaneous Harding-Passey melanoma xenografts. When diet supplementation with coconut oil and cholesterol for 21 days and regular dosing with hydrocortisone for 7 days before the studies was used to down-regulate the liver LDL receptors and the adrenal receptors, respectively, the tumour-blood boron concentration ratio of 5:1 was achieved.
The concept of using plasma low-density lipoprotein (LDL) as a cancer-targeted drug carrier system has been stimulated by the discovery that leukaemic cells from the peripheral blood of patients with acute myelogenous leukaemia had 3-100 times higher LDL receptor activity than normal white blood cells (Ho et al., 1978) . Since then, a number of studies have demonstrated that a variety of human cancers, including cervical, lung and brain tumours, take up LDL at a rate greater than the corresponding normal tissue (for a review see Firestone, 1994) .
The adaptation of LDL as a boron carrier for boron neutron capture therapy (BNCT) of cancer has been pioneered by Kahl and co-workers, who described the extraction of the cholesterol ester core and reconstitution with various carborane compounds (Kahl and Callaway, 1989) . The boronated LDL retained its ability to be taken up strongly into hamster V79 and CHO cells in culture, achieving boron concentrations consistent with a receptormediated binding mechanism (Laster et al., 1991) . Subsequent in vitro neutron irradiation confirmed the efficacy of the boron neutron capture reaction in killing the cells. However, in vivo studies of boronated LDL with hamster V79 and CHO cell xenografts in mice did not show selective localisation of boron in the cells (Kahl et al., 1993) .
In this paper, it is shown for the first time that boronated LDL can act as a novel boron delivery system in BNCT, following suppression of the non-autonomous LDL receptors.
Materials and methods Preparation of boronated LDL Human LDL (density 1.019-1.063 g ml-') was isolated by two-step density ultracentrifugation from fresh human plasma using standard procedures (Havel et al., 1955) . The boronated LDL was prepared by extracting the lipid core of LDL with heptane, then reconstituting according to the method of Masquelier et al. (1986) with n-octyl ['0B]-carborane, which was synthesised in our laboratory (Smith et al., 1996) . Briefly, the procedure was as follows. LDL (300 ,ul containing 2 mg of LDL protein) was transferred into a silanised glass tube (13 x 100 mm). The LDL was lyophilised in the presence of sucrose (25%, w/v) as cryoprotectant for 6 h, then extracted three times with 5 ml heptane at 4°C with repeated agitation every 10 min for 1 h. n-Octyl carborane (20 mg in 1 ml heptane) was combined with the dried heptane extract and mixed with the extracted LDL by gentle agitation at 4°C. After 1 h, the heptane was evaporated under nitrogen and the drug-LDL complex was solubilised by the addition of 1 ml of 10 mM tricine buffer pH 8.4, and left overnight at 4°C. Insoluble nonincorporated drug was separated by centrifuging at 4°C for 5 min in an Eppendorf centrifuge and, finally, the boronated LDL preparation was filtered through a 0.45 ,um membrane filter.
Pharmacokinetics of the boronated LDL drug carrier system in melanoma-bearing mice Adult male BALB/c mice at 6-8 weeks of age weighing 25-30 g were housed under a normal light-dark cycle, and provided with diet and water ad libitum. One group of mice was fed Gordon's Pelletised Animal Feed (Brisbane, Australia), while the remainder were fed for 3 weeks before the pharmacokinetic study with the same feed supplemented with 2% (w/w) cholesterol and 10% (w/w) coconut oil (cholesterol was dissolved in melted coconut oil at 100°C and mechanically mixed into the pelletised animal feed). This diet was employed to down-regulate the non-autonomous liver LDL receptors. In addition, to down-regulate the adrenal LDL receptors, a daily intraperitoneal (i.p.) injection of hydrocortisone sodium succinate (5 mg per mouse) was given for 7 days before each study (Ponty et al., 1993) . The oilenriched feed was continued throughout the studies. In 3 weeks the mice (initial weight 17.67+0.53 g, n=20) had gained an average of 3.3 + 1.2 g (n = 10) in weight when 'dietsupplemented', compared with a weight gain of 3.0+1.3 g (n = 10) for the mice fed the normal diet for the same period, a difference which is not significant (P=0.19).
Tumour induction in the BALB/c mice was achieved by inoculating 0.1 ml of medium containing 106 HardingPassey melanoma cells subcutaneously in the right thigh. After a period of 7 days the tumours had grown to an approximate diameter of 2 mm (20-70 mg) and the mice were then injected i.p. with 1 ml of boronated LDL, equivalent to 4 mg of n-octyl carborane. At different times the mice were sacrificed and tissue samples of 20 -100 mg (blood, liver, kidney, spleen, brain, tumour and skin and muscle adjacent to the tumour) were collected for each animal. The samples were weighed directly into polythene vials and digested in a water bath for 1 h at 70°C with 0.5 ml of perchloric acid (70%) and 1 ml of hydrogen peroxide (28%) (Tamat et al., 1987 Figure 1 . The kidney and spleen values followed the same trend as the liver, but were about half the magnitude, while brain uptake of boron was less than in the skin/muscle samples. The pharmacokinetic data shown in Table I illustrate the profound changes arising from the diet supplementation. The elimination constant (kei) and half-life (t1/2) of the boron concentration in the blood following administration of B-LDL to normal (group ND) and diet-supplemented (group Study B The pharmacokinetics of boron uptake for boronated-LDL and the carborane in arachis oil for dietsupplemented mice are quite different, as shown in Figure 2a and b. As in study A, only the data for blood, liver, tumour and skin/muscle are shown. In principle, the use of boronated LDL can be optimised further by i.v. administration of a more concentrated preparation and further down-regulation of the LDL receptors, so that the potential to achieve therapeutic concentrations of boron in the tumour (>20 p.p.m. boron in the tumour) leading to successful control with neutron irradiation may be realised.
In current trials of neutron capture therapy, brain tumours are the clinical target, so the question arises as to the potential of boronated LDL to deliver boron to the brain. Normal brain is not expected to allow the passage of these large entities, and our results showed clearly that brain boron concentrations were less than that in blood. However, other studies have shown that several different types of brain tumour bind two to three times more LDL than normal brain, indicating that the blood -brain barrier may be significantly more permeable around the tumour (Rudling et al., 1990) . On this basis, the further investigation of LDL for boron delivery in BNCT is warranted.
